Vilazodone for Treatment of Geriatric Depression

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Los Angeles
• Collaborator: Forest Laboratories
• Treatments: Antidepressive Agents; Paroxetine; Vilazodone Hydrochloride

Criteria

Inclusion Criteria:

• 60 years of age or older

• The presence of a major depressive disorder diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria

• A 24-item Hamilton Depression Rating Scale (HAMD) score of 17 or higher at baseline

• Mini-Mental State Exam (MMSE) score > 24.

Exclusion Criteria:

• Subjects will be excluded if they had any current and/or lifetime history of other psychiatric disorders (except unipolar depression with or without comorbid generalized anxiety disorder), or recent unstable medical or neurological disorders; any disabilities preventing their participation in the study; diagnosis of mild cognitive impairment (MCI)/dementia; those with known allergic reactions to paroxetine or vilazodone.